Page 26 - 《中国药房》2025年22期
P. 26

·药学研究·


          基于血清药物化学与网络药理学的鸡骨草和毛鸡骨草抗肝炎作
          用机制研究
                            Δ


                                                                             1 #
                                                                     2
                 1*
                                                    1
                                   1
          周巧雯 ,王 雪 ,黄明娟 ,黎 理 ,陈文雅 ,王峥涛 ,张紫佳 ,樊兰兰 (1. 广西中医药大学药学院,南宁
                                                            2
                                            1
                           1
          530200;2.上海中医药大学中药研究所上海市复方中药重点实验室,上海 201203)
          中图分类号  R284;R285      文献标志码  A      文章编号  1001-0408(2025)22-2772-06
          DOI  10.6039/j.issn.1001-0408.2025.22.04
          摘   要  目的  比较鸡骨草与毛鸡骨草抗肝炎的作用机制。方法  将SD大鼠随机分为空白组、鸡骨草给药组和毛鸡骨草给药组,
          每组10只。各组分别于灌胃24 g/kg相应药物(以生药量计)或水5、15、30 min及1、1.5、2、4、6、8、12 h时,采集大鼠眼眶静脉血,采
          用超高效液相色谱-四极杆飞行时间质谱联用技术鉴定含药血清中的原型成分;利用网络药理学方法,预测鸡骨草与毛鸡骨草抗
          肝炎的活性成分、关键靶点及信号通路;利用分子对接技术验证活性成分与关键靶点的结合活性。结果  在鸡骨草、毛鸡骨草含药
          血清中分别鉴定出35种原型成分,其中24种为共有成分。鸡骨草中的acetylanguidine、大黄素甲醚、大豆皂苷A3和大豆皂苷Ⅰ等
          活性成分,以及毛鸡骨草中的维采宁3、acetylanguidine、大豆皂苷Ⅰ和夏佛塔苷等活性成分,均作用于类固醇受体共激活因子、磷
          脂酰肌醇4,5-二磷酸3-激酶催化亚基α、表皮生长因子受体(EGFR)和蛋白激酶B1(Akt1)等关键靶点,通过调控癌症相关信号通
          路、EGFR酪氨酸激酶抑制剂耐药性以及磷脂酰肌醇3激酶-Akt(PI3K-Akt)通路,发挥抗肝炎作用,且活性成分与关键靶点的结合
          能均小于-5 kJ/mol。结论  鸡骨草与毛鸡骨草抗肝炎的活性成分存在差异,但其作用机制相似,二者可能均通过调控癌症相关信
          号通路、EGFR酪氨酸激酶抑制剂耐药性以及PI3K-Akt通路发挥抗肝炎作用。
          关键词  鸡骨草;毛鸡骨草;抗肝炎;血清药物化学;网络药理学;分子对接;作用机制

          Study  on  the  anti-hepatitis  mechanism  of Abrus  pulchellus  subsp.  cantoniensis (Hance)  Verdc.  and Abrus
          pulchellus subsp. mollis (Hance) Verdc. based on serum pharmacochemistry and network pharmacology
                                                                                              2
                                                                             1
                                                              1
                                                                                                            2
                                     1
                        1
                                                        1
          ZHOU Qiaowen ,WANG Xue ,HUANG Mingjuan ,LI Li ,CHEN Wenya ,WANG Zhengtao ,ZHANG Zijia ,
          FAN Lanlan(1.  College  of  Pharmacy,  Guangxi  University  of  Chinese  Medicine,  Nanning  530200,  China;
                     1
          2.  Shanghai  Key  Laboratory  of  Compound  Chinese  Medicines,  Institute  of  Chinese  Materia  Medica,  Shanghai
          University of Traditional Chinese Medicine, Shanghai 201203, China)
          ABSTRACT    OBJECTIVE  To  compare  the  anti-hepatitis  mechanisms  of  Abrus  pulchellus  subsp.  cantoniensis (Hance)  Verdc.
         (AC) and Abrus pulchellus subsp. mollis(Hance) Verdc. (AM). METHODS SD rats were randomly divided into blank group, AC-
          treated group, and AM-treated group, with each group consisting of 10 rats. The rats’ orbital venous blood was collected at 5, 15,
          30  minutes,  and  1,  1.5,  2,  4,  6,  8,  12  hours  after  gavage  administration  of  24  g/kg  of  the  corresponding  drug (calculated  by
          crude  drug)  or  water,  respectively.  Ultra-performance  liquid  chromatography-quadrupole  time-of-flight  mass  spectrometry
          technology was utilized to identify the prototype components present in the serum. The network pharmacology method was adopted
          to  predict  the  anti-hepatitis  active  components,  key  targets,  and  signaling  pathways  of  AC  and  AM.  Additionally,  molecular
          docking technology was utilized to verify the binding activity of the core active components with key targets. RESULTS A total of
          35 prototype components migrating to the blood of AC and AM were identified in the serum of administered rats, among which 24
          were common components. The active components in AC, such as acetylanguidine, physcion, soyasaponin A3 and soyasaponin Ⅰ,
                                                              as well as those in AM, including vicenin 3, acetylanguidine,
              Δ 基金项目 国家自然科学基金项目(No.82360739);广西科技计            soyasaponin  Ⅰ  and  schaftoside,  all  acted  on  key  targets  such
          划项目(No.桂科AA23023035);广西壮族自治区高校黄大年式教师团
                                                              as  steroid  receptor  coactivator,  phosphatidylinositol-4,5-
          队“中药学传承创新教师团队”项目(No.桂教教师〔2023〕31号);广西
                                                              bisphosphate  3-kinase  catalytic  subunit  alpha,  epidermal
          中 医 药 大 学 - 柳 药 集 团 青 年 科 技 创 新 能 力 提 升 计 划 专 项(No.
                                                              growth  factor  receptor  (EGFR),  and  protein  kinase  B1
          YXY0000303);上海市复方中药重点实验室(上海中医药大学)开放基
                                                             (Akt1).  These  components  modulated  pathways  in  cancer,
          金项目(No.2023OPCCMSHUTCM-06)
             * 第一作者 硕 士 研 究 生 。 研 究 方 向 :中 药 分 析 。 E-mail:    EGFR   tyrosine   kinase   inhibitor   resistance,   and   the
          2834645195@qq.com                                   phosphoinositide  3-kinase  (PI3K) -Akt  pathway,  thereby
              # 通信作者 教授,博士生导师。研究方向:中药、民族药质量控                  exerting  anti-hepatitis  effects.  Furthermore,  the  binding
          制。E-mail:fanll2015@gxtcmu.edu.cn                    energies between these active components and their key targets


          · 2772 ·    China Pharmacy  2025 Vol. 36  No. 22                            中国药房  2025年第36卷第22期
   21   22   23   24   25   26   27   28   29   30   31